Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent B-Cell Non-Hodgkin's Lymphomas”

169 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 169 results

Testing effectiveness (Phase 2)Study completedNCT00244985
What this trial is testing

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Roswell Park Cancer Institute 42
Testing effectiveness (Phase 2)Study completedNCT00720876
What this trial is testing

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
City of Hope Medical Center 30
Early research (Phase 1)Active Not RecruitingNCT05878184
What this trial is testing

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Who this might be right for
Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Sana Biotechnology 16
Large-scale testing (Phase 3)Ended earlyNCT04745832
What this trial is testing

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Who this might be right for
Follicular Lymphoma (FL)Non Hodgkin LymphomaMarginal Zone Lymphoma
MEI Pharma, Inc. 82
Large-scale testing (Phase 3)Active Not RecruitingNCT03984448
What this trial is testing

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Who this might be right for
Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedDouble-Expressor Lymphoma+5 more
National Cancer Institute (NCI) 363
Early research (Phase 1)WithdrawnNCT05934097
What this trial is testing

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaTransformed Indolent Non-Hodgkin's LymphomaFollicular Lymphoma+2 more
Fate Therapeutics
Testing effectiveness (Phase 2)UnknownNCT00927797
What this trial is testing

Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)

Who this might be right for
Immunocytoma/Morbus WaldenströmB-Cell Non-Hodgkin's LymphomaB-Cell Chronic Lymphocytic Leukemia
Heidelberg University 185
Testing effectiveness (Phase 2)Study completedNCT03019640
What this trial is testing

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Mantle Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+4 more
M.D. Anderson Cancer Center 22
Early research (Phase 1)Study completedNCT01410513
What this trial is testing

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Sanofi 37
Early research (Phase 1)WithdrawnNCT02640833
What this trial is testing

Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNon-Hodgkin Lymphoma
AbbVie
Early research (Phase 1)Active Not RecruitingNCT06824701
What this trial is testing

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah 24
Testing effectiveness (Phase 2)Study completedNCT00081809
What this trial is testing

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

Who this might be right for
Lymphoma, FollicularLymphoma, Small Lymphocytic
Agenus Inc. 35
Early research (Phase 1)Study completedNCT00012207
What this trial is testing

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Fred Hutchinson Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT00295932
What this trial is testing

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 79
Testing effectiveness (Phase 2)Study completedNCT00875056
What this trial is testing

Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)

Who this might be right for
Lymphoma
Merck Sharp & Dohme LLC 56
Very early researchStudy completedNCT02846935
What this trial is testing

P53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Who this might be right for
T-cell LymphomaAggressive B-cell LymphomaNon-Hodgkin's Lymphomas+1 more
Yogen Saunthararajah 7
Early research (Phase 1)Study completedNCT03424603
What this trial is testing

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Who this might be right for
B-cell LymphomaNon Hodgkin LymphomaMultiple Myeloma+5 more
Sutro Biopharma, Inc. 70
Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Large-scale testing (Phase 3)Ended earlyNCT01732913
What this trial is testing

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Who this might be right for
Indolent Non-Hodgkin's Lymphomas
Gilead Sciences 295
Early research (Phase 1)UnknownNCT03823365
What this trial is testing

Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
A.O. Ospedale Papa Giovanni XXIII 19
Next Page